These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 17974866)

  • 1. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
    Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
    Passmore AP; Bayer AJ; Steinhagen-Thiessen E
    J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.
    Seltzer B; Zolnouni P; Nunez M; Goldman R; Kumar D; Ieni J; Richardson S;
    Arch Neurol; 2004 Dec; 61(12):1852-6. PubMed ID: 15596605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials.
    Winblad B; Black SE; Homma A; Schwam EM; Moline M; Xu Y; Perdomo CA; Swartz J; Albert K
    Curr Med Res Opin; 2009 Nov; 25(11):2577-87. PubMed ID: 19735164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil.
    Jones RW; Schwam E; Wilkinson D; Waldemar G; Feldman HH; Zhang R; Albert K; Schindler R
    Alzheimer Dis Assoc Disord; 2009; 23(4):357-64. PubMed ID: 19561444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
    Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
    Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
    Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
    Tei E; Yamamoto H; Watanabe T; Miyazaki A; Nakadate T; Kato N; Mimura M
    Growth Horm IGF Res; 2008 Feb; 18(1):47-54. PubMed ID: 17714966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
    Fuh JL; Wang SJ
    Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donepezil treatment in ethnically diverse patients with Alzheimer disease.
    Tinklenberg JR; Kraemer HC; Yaffe K; O'Hara R; Ringman JM; Ashford JW; Yesavage JA; Taylor JL;
    Am J Geriatr Psychiatry; 2015 Apr; 23(4):384-390. PubMed ID: 25747405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH; Schmitt FA; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on Alzheimer drugs (donepezil).
    Smith Doody R
    Neurologist; 2003 Sep; 9(5):225-9. PubMed ID: 12971832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
    Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
    Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
    Tanaka M; Namiki C; Thuy DH; Yoshida H; Kawasaki K; Hashikawa K; Fukuyama H; Kita T
    J Neurol Sci; 2004 Oct; 225(1-2):135-41. PubMed ID: 15465097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
    Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L;
    Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.